Is there enough data to recommend #rituximab For #ILD in #rheumatoid #arthritis @RheumNow #EULAR2026

TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX

• https://x.com/RHEUMarampa/status/2063162488732934213/photo/1

#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi

• 5 years since Patient ID001: Progress on CAR-T Therapy in RMD | RheumNow
• https://x.com/Yuz6Yusof/status/2063141761061400974/photo/1

One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu

• This Is a Woman’s World: Women's Health in Rheumatic Disease
• https://x.com/Nellziade/status/2062965329496539425/photo/1

#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV

• https://x.com/Yuz6Yusof/status/2063192348499034168/photo/1

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

• https://x.com/Yuz6Yusof/status/2062889577862344849/photo/1

A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

• https://x.com/AurelieRheumo/status/2062922909606175060/photo/1
• https://x.com/AurelieRheumo/status/2062922909606175060/photo/1

Can we have an effective, comprehensive score for #SLE #arthritis? #SLEDAI has a problem SJC>2 scores dames as ex #SJC=12 Meet #LAMBDA An attempt to improve a true positive #MSK OUTCOME in #lupus Needs validation esp in pts over time #EULAR2026 @RheumNow #POS1072 @eular_org https://t.co/fr0xuVqFnM

• https://x.com/Janetbirdope/status/2062877860562346175/photo/1

#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

• https://x.com/Yuz6Yusof/status/2062886696459346275/photo/1

#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS

• https://x.com/Yuz6Yusof/status/2062878356006166772/photo/1

#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284